Insider Selling: ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells 2,801 Shares of Stock

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Jacob Chacko sold 2,801 shares of the company’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $25.02, for a total transaction of $70,081.02. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jacob Chacko also recently made the following trade(s):

  • On Friday, September 10th, Jacob Chacko sold 2,942 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $25.08, for a total transaction of $73,785.36.
  • On Tuesday, September 7th, Jacob Chacko sold 5,981 shares of ORIC Pharmaceuticals stock. The stock was sold at an average price of $25.11, for a total transaction of $150,182.91.

NASDAQ:ORIC opened at $24.96 on Wednesday. The firm has a market cap of $981.38 million, a price-to-earnings ratio of -9.24 and a beta of 2.91. ORIC Pharmaceuticals, Inc. has a 52 week low of $15.67 and a 52 week high of $40.81. The firm has a 50-day moving average price of $19.53 and a two-hundred day moving average price of $22.26.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Tuesday, August 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08). Analysts expect that ORIC Pharmaceuticals, Inc. will post -2.24 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. increased its stake in shares of ORIC Pharmaceuticals by 18.0% during the 2nd quarter. Victory Capital Management Inc. now owns 1,304,360 shares of the company’s stock worth $23,074,000 after purchasing an additional 198,986 shares during the last quarter. Millennium Management LLC grew its stake in ORIC Pharmaceuticals by 21.2% in the 1st quarter. Millennium Management LLC now owns 123,457 shares of the company’s stock valued at $3,025,000 after buying an additional 21,595 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ORIC Pharmaceuticals in the 1st quarter valued at approximately $40,000. Point72 Asset Management L.P. purchased a new position in ORIC Pharmaceuticals in the 1st quarter valued at approximately $31,498,000. Finally, New York State Common Retirement Fund grew its stake in ORIC Pharmaceuticals by 16.8% in the 1st quarter. New York State Common Retirement Fund now owns 21,500 shares of the company’s stock valued at $527,000 after buying an additional 3,100 shares in the last quarter. Institutional investors own 91.96% of the company’s stock.

A number of equities analysts have recently issued reports on ORIC shares. HC Wainwright cut their price objective on shares of ORIC Pharmaceuticals from $54.00 to $53.00 and set a “buy” rating on the stock in a research report on Wednesday, August 11th. raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price objective on the stock in a research report on Tuesday, July 6th. Citigroup raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Tuesday, July 6th. Zacks Investment Research cut shares of ORIC Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, raised shares of ORIC Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Tuesday, July 6th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $37.00.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.

Recommended Story: What is the Quick Ratio?

Insider Buying and Selling by Quarter for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.